Skip to content

Study · Randomized controlled trial · n = 91 · 1994

7 results

Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.

Overgaard K

Calcified tissue international1 Aug 1994Cited by 46 (Europe PMC)

PMID7953984 (opens in a new tab)DOI10.1007/bf00297179 (opens in a new tab)PepBankPUB-07953984
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal women, lumbar spine bone density at 24 months did not differ significantly between treatment groups.

    In plain wordsIn early postmenopausal women, spine bone density at 24 months did not differ significantly between treatment groups.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeLumbar spine bone density at 24 months
    Study

    n = 91

    Comparator
    Placebo and other calcitonin doses
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100, 200, or 400 IU · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Although the measurements after 24 months revealed no significant difference between groups in bone mineral density of the lumbar spine,
    2 context sentences
    Summary · context
    The women were allocated randomly to 2 years of treatment with either 100, 200, or 400 IU of sCT given intranasally or placebo.
    Summary · context
    All groups received a calcium supplement of 500 mg.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal women, calcitonin showed no dose-related response.

    In plain wordsIn early postmenopausal women, calcitonin showed no dose-related response.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeDose response
    Study

    n: not reported in source

    Comparator
    Other calcitonin doses
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100, 200, or 400 IU · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    There was no dose-related response to sCT but
    2 context sentences
    Summary · context
    The women were allocated randomly to 2 years of treatment with either 100, 200, or 400 IU of sCT given intranasally or placebo.
    Summary · context
    All groups received a calcium supplement of 500 mg.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal women, pooled higher calcitonin doses differed significantly from low-dose calcitonin and placebo (P = 0.030-0.005).

    In plain wordsIn early postmenopausal women, pooled higher calcitonin doses differed from low-dose calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicablePooled bone density comparison
    Study

    n: not reported in source

    Comparator
    100 IU calcitonin and placebo pooled
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 plus 400 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    P value
    0.005 to 0.03
    200 plus 400 IU sCT versus 100 IU sCT and placebo pooled

    Source sentences

    Summary
    There was no dose-related response to sCT but there was a significant difference between the pooled groups treated with 200 plus 400 IU of sCT versus the 100 IU sCT and placebo-treated groups (P = 0.030-0.005).
    2 context sentences
    Summary · context
    The women were allocated randomly to 2 years of treatment with either 100, 200, or 400 IU of sCT given intranasally or placebo.
    Summary · context
    All groups received a calcium supplement of 500 mg.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal women, the same pooled group difference occurred for biochemical bone turnover parameters (P = 0.022-0.003).

    In plain wordsIn early postmenopausal women, bone turnover markers differed between pooled higher doses and pooled low-dose calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicablePooled bone turnover parameter comparison
    Study

    n: not reported in source

    Comparator
    100 IU calcitonin and placebo pooled
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 plus 400 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    P value
    0.003 to 0.022
    200 plus 400 IU sCT versus 100 IU sCT and placebo pooled, biochemical bone turnover parameters

    Source sentences

    Summary
    The same difference between groups was seen for biochemical parameters of bone turnover (P = 0.022-0.003).
    3 context sentences
    Summary · context
    There was no dose-related response to sCT but there was a significant difference between the pooled groups treated with 200 plus 400 IU of sCT versus the 100 IU sCT and placebo-treated groups (P = 0.030-0.005).
    Summary · context
    The women were allocated randomly to 2 years of treatment with either 100, 200, or 400 IU of sCT given intranasally or placebo.
    Summary · context
    All groups received a calcium supplement of 500 mg.
  5. 05HumanNon-randomized trialEfficacy outcome

    In early postmenopausal women, the two higher calcitonin doses prevented bone loss, with average changes of 0.2 to -0.6%.

    In plain wordsIn early postmenopausal women, the two higher calcitonin doses prevented average spine bone loss.

    Peptide
    Calcitonin-salmon
    Outcome
    MixedAverage lumbar spine bone density change
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 and 400 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Average change in lumbar spine bone density
    −0.6 to 0.2%
    200 and 400 IU sCT groups, over time

    Source sentences

    Summary
    the average changes over time revealed prevention of bone loss in the groups treated with 200 and 400 IU of sCT (0.2 to -0.6%)
    2 context sentences
    Summary · context
    The women were allocated randomly to 2 years of treatment with either 100, 200, or 400 IU of sCT given intranasally or placebo.
    Summary · context
    All groups received a calcium supplement of 500 mg.
  6. 06HumanNon-randomized trialEfficacy outcome

    In early postmenopausal women, the low calcitonin dose and placebo groups showed declines of 0.8-1.7% (P < 0.05-0.01; within-group testing).

    In plain wordsIn early postmenopausal women, spine bone density declined in both the low-dose calcitonin and placebo groups.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseAverage lumbar spine bone density decline
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Decline in lumbar spine bone density
    0.8 to 1.7%
    100 IU sCT and placebo groups, within-group testing

    Source sentences

    Summary
    and declines of 0.8-1.7% in the groups treated with 100 IU of sCT and placebo (P < 0.05-0.01; within-group testing).
    2 context sentences
    Summary · context
    The women were allocated randomly to 2 years of treatment with either 100, 200, or 400 IU of sCT given intranasally or placebo.
    Summary · context
    All groups received a calcium supplement of 500 mg.
  7. 07HumanNon-randomized trialEfficacy outcome

    In early postmenopausal women, the two highest calcitonin doses reduced biochemical bone turnover parameters by 10-20% (P < 0.001).

    In plain wordsIn early postmenopausal women, bone turnover markers decreased with the two highest calcitonin doses.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseBone turnover parameter change
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 and 400 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Decrease in biochemical bone turnover parameters
    10 to 20%
    200 and 400 IU sCT groups, within-group testing

    Source sentences

    Summary
    The biochemical parameters of bone turnover revealed decreases of 10-20% (P < 0.001; within group testing) in the groups treated with the two highest sCT doses.(ABSTRACT TRUNCATED AT 250 WORDS)
    2 context sentences
    Summary · context
    The women were allocated randomly to 2 years of treatment with either 100, 200, or 400 IU of sCT given intranasally or placebo.
    Summary · context
    All groups received a calcium supplement of 500 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.